KR102782200B1 - 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드 - Google Patents

인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드 Download PDF

Info

Publication number
KR102782200B1
KR102782200B1 KR1020207008457A KR20207008457A KR102782200B1 KR 102782200 B1 KR102782200 B1 KR 102782200B1 KR 1020207008457 A KR1020207008457 A KR 1020207008457A KR 20207008457 A KR20207008457 A KR 20207008457A KR 102782200 B1 KR102782200 B1 KR 102782200B1
Authority
KR
South Korea
Prior art keywords
formula
delete delete
alkyl
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207008457A
Other languages
English (en)
Korean (ko)
Other versions
KR20200058411A (ko
Inventor
안롱 리
시아오치 첸
윈타오 송
Original Assignee
에이제이 사이언시즈 (이씽) 코., 엘티디
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에이제이 사이언시즈 (이씽) 코., 엘티디 filed Critical 에이제이 사이언시즈 (이씽) 코., 엘티디
Publication of KR20200058411A publication Critical patent/KR20200058411A/ko
Application granted granted Critical
Publication of KR102782200B1 publication Critical patent/KR102782200B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/213—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H23/00—Compounds containing boron, silicon or a metal, e.g. chelates or vitamin B12

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
KR1020207008457A 2017-08-30 2018-08-30 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드 Active KR102782200B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762552148P 2017-08-30 2017-08-30
US62/552,148 2017-08-30
US201862660565P 2018-04-20 2018-04-20
US62/660,565 2018-04-20
PCT/IB2018/056658 WO2019043634A2 (en) 2017-08-30 2018-08-30 CYCLIC DI-NUCLEOTIDES AS STIMULATORS OF INTERFERON GENE MODULATORS

Publications (2)

Publication Number Publication Date
KR20200058411A KR20200058411A (ko) 2020-05-27
KR102782200B1 true KR102782200B1 (ko) 2025-03-17

Family

ID=65527221

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207008457A Active KR102782200B1 (ko) 2017-08-30 2018-08-30 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드

Country Status (14)

Country Link
US (1) US11773132B2 (https=)
EP (1) EP3692048A4 (https=)
JP (1) JP7311514B2 (https=)
KR (1) KR102782200B1 (https=)
CN (1) CN111263767B (https=)
AU (1) AU2018323053A1 (https=)
BR (1) BR112020004047A2 (https=)
CA (1) CA3073919A1 (https=)
IL (1) IL272928A (https=)
MX (1) MX2020002303A (https=)
RU (1) RU2020112502A (https=)
SG (1) SG11202001847WA (https=)
TW (1) TWI808092B (https=)
WO (1) WO2019043634A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
WO2018156625A1 (en) 2017-02-21 2018-08-30 Board Of Regents,The University Of Texas System Cyclic dinucleotides as agonists of stimulator of interferon gene dependent signalling
MX2020002303A (es) 2017-08-30 2020-09-10 Beijing Xuanyi Pharmasciences Co Ltd Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
KR20200098511A (ko) 2017-11-10 2020-08-20 다케다 야쿠힌 고교 가부시키가이샤 Sting 조절제 화합물, 및 제조 및 사용 방법
ES2980374T3 (es) * 2018-03-08 2024-10-01 Bristol Myers Squibb Co Dinucleótidos cíclicos como agentes anticancerosos
BR112020024605A2 (pt) 2018-06-01 2021-04-06 Eisai R&D Management Co., Ltd. Métodos para o tratamento de câncer de bexiga
CN112867727B (zh) * 2018-10-12 2024-05-17 上海济煜医药科技有限公司 环二核苷酸类化合物及其应用
US12435104B2 (en) * 2019-07-25 2025-10-07 Beigene, Ltd. Cyclic dinucleotides as sting agonists
EP4114417A4 (en) * 2020-03-06 2024-08-14 OD Therapeutics Limited THERAPEUTIC AGENTS AND THEIR CONJUGATES
TW202200136A (zh) 2020-04-10 2022-01-01 日商小野藥品工業股份有限公司 癌治療方法
CN111592570B (zh) * 2020-05-15 2022-04-29 清华大学 新型sting激动剂及其制备方法和应用
TWI901793B (zh) * 2020-10-20 2025-10-21 大陸商泰勵生物科技（上海）有限公司 多功能環二核苷酸及其用途
KR102466750B1 (ko) * 2020-10-23 2022-11-15 아주대학교산학협력단 인돌리진 유도체를 유효성분으로 포함하는 인터페론 유전자 자극제 조성물
IL302390A (en) 2020-11-09 2023-06-01 Takeda Pharmaceuticals Co Drug antibody conjugates

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500697A (ja) * 2003-07-28 2007-01-18 デイビッド・ケイ・アール・カラオリス 微生物病原体の毒性を減弱させる方法、および微生物のバイオフィルム形成を阻害する方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9518953D0 (en) 1995-09-15 1995-11-15 Pfizer Ltd Pharmaceutical formulations
WO2000035296A1 (en) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Improved release of medicament active agents from a chewing gum coating
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
DE60332483D1 (de) 2002-11-15 2010-06-17 Novartis Vaccines & Diagnostic Methoden zur verhinderung und behandlung von krebs-metastasierung und mit krebs-metastasierung einhergehendem knochenverlust
JPWO2005005450A1 (ja) 2003-07-15 2006-08-24 三井化学株式会社 環状ビスジヌクレオチドの合成方法
WO2005089777A1 (en) 2004-03-15 2005-09-29 Karaolis David K R A method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
AR064801A1 (es) 2006-08-18 2009-04-29 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
ES2582340T3 (es) 2008-01-15 2016-09-12 The Board Of Trustees Of The Leland Stanford Junior University Métodos para manipular fagocitosis mediada por CD47
EP2111869A1 (en) 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
WO2009133560A1 (en) 2008-04-29 2009-11-05 Smart Assays Non-hydrolyzable and permeable cyclic bis-[nucleotide monophosphate] derivatives and uses thereof
CA2754127C (en) 2009-03-02 2017-04-18 Stichting Top Institute Pharma Antibodies against a proliferating inducing ligand (april)
AU2011290672B2 (en) 2010-08-20 2015-07-09 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3)
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
US9840533B2 (en) 2013-04-29 2017-12-12 Memorial Sloan Kettering Cancer Center Compositions and methods for altering second messenger signaling
PE20160080A1 (es) 2013-05-18 2016-02-21 Aduro Biotech Inc Composiciones y metodos para activar la senalizacion que depende del estimulador del gen de interferon
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
CA2927009C (en) 2013-10-21 2019-04-23 Drexel University Use of sting agonists to treat chronic hepatitis b virus infection
WO2015074145A1 (en) 2013-11-22 2015-05-28 Brock University Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants
CR20160564A (es) 2014-06-04 2017-01-20 Glaxosmithkline Ip Dev Ltd Dinucleótidos cíclicos como moduladores de sting
WO2016096577A1 (en) 2014-12-16 2016-06-23 Invivogen Combined use of a chemotherapeutic agent and a cyclic dinucleotide for cancer treatment
EP3546473B1 (en) * 2014-12-16 2025-12-10 Kayla Therapeutics Fluorinated cyclic [(2',5')p(3',5')p]-dinucleotides for cytokine induction
GB201501462D0 (en) * 2015-01-29 2015-03-18 Glaxosmithkline Ip Dev Ltd Novel compounds
EA035817B1 (ru) * 2015-03-10 2020-08-14 Адуро Байотек, Инк. Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона"
KR102222186B1 (ko) 2015-08-13 2021-03-03 머크 샤프 앤드 돔 코포레이션 Sting 효능제로서 시클릭 디-뉴클레오티드 화합물
JP2018534295A (ja) 2015-10-28 2018-11-22 アドゥロ バイオテック，インク． 「インターフェロン遺伝子刺激因子」依存性シグナル伝達を活性化するための組成物および方法
CN107849084B (zh) 2015-12-03 2021-09-14 葛兰素史密斯克莱知识产权发展有限公司 作为sting调节剂的环状嘌呤二核苷酸
US20180369268A1 (en) 2015-12-16 2018-12-27 Aduro Biotech, Inc. Methods for identifying inhibitors of "stimulator of interferon gene"- dependent interferon production
US10723756B2 (en) 2016-01-11 2020-07-28 Innate Tumor Immunity Inc. Cyclic dinucleotides for treating conditions associated with STING activity such as cancer
KR102789862B1 (ko) 2016-01-11 2025-04-03 인네이트 튜머 이뮤니티, 인코포레이티드 Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
NZ746112A (en) 2016-03-18 2023-01-27 Immune Sensor Llc Cyclic di-nucleotide compounds and methods of use
EP3448393A1 (en) * 2016-04-25 2019-03-06 Invivogen Novel complexes of immunostimulatory compounds, and uses thereof
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
US20190345191A1 (en) 2016-08-31 2019-11-14 Innate Tumor Immunity, Inc. Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
US10537590B2 (en) 2016-09-30 2020-01-21 Boehringer Ingelheim International Gmbh Cyclic dinucleotide compounds
US11001605B2 (en) * 2016-10-07 2021-05-11 Biolog Life Science Institute Gmbh & Co. Kg Cyclic dinucleotides containing benzimidazole, method for the production of same, and use of same to activate stimulator of interferon genes (sting)-dependent signaling pathways
JOP20170188A1 (ar) * 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
PE20210255A1 (es) 2016-12-01 2021-02-10 Takeda Pharmaceuticals Co Dinucleotido ciclico como agonistas de sting (estimulador de genes de interferon)
WO2018118665A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Cyclic dinucleotide sting agonists for cancer treatment
CN110167566A (zh) * 2016-12-21 2019-08-23 弗莱德哈钦森癌症研究中心 治疗实体瘤细胞和逃避变体的支架
US11021511B2 (en) 2017-01-27 2021-06-01 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
CN110234403A (zh) * 2017-01-27 2019-09-13 詹森生物科技公司 作为sting激动剂的环状二核苷酸
MX2020002303A (es) 2017-08-30 2020-09-10 Beijing Xuanyi Pharmasciences Co Ltd Dinucleotidos ciclicos como moduladores del estimulador de genes de interferon.
CN112867727B (zh) * 2018-10-12 2024-05-17 上海济煜医药科技有限公司 环二核苷酸类化合物及其应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007500697A (ja) * 2003-07-28 2007-01-18 デイビッド・ケイ・アール・カラオリス 微生物病原体の毒性を減弱させる方法、および微生物のバイオフィルム形成を阻害する方法

Also Published As

Publication number Publication date
US11773132B2 (en) 2023-10-03
WO2019043634A2 (en) 2019-03-07
CN111263767A (zh) 2020-06-09
BR112020004047A2 (pt) 2020-09-01
AU2018323053A1 (en) 2020-03-19
IL272928A (en) 2020-04-30
WO2019043634A3 (en) 2019-04-11
SG11202001847WA (en) 2020-03-30
JP7311514B2 (ja) 2023-07-19
CA3073919A1 (en) 2019-03-07
JP2020532585A (ja) 2020-11-12
TW201919650A (zh) 2019-06-01
TWI808092B (zh) 2023-07-11
RU2020112502A (ru) 2021-10-01
US20200331957A1 (en) 2020-10-22
CN111263767B (zh) 2023-07-18
KR20200058411A (ko) 2020-05-27
MX2020002303A (es) 2020-09-10
EP3692048A2 (en) 2020-08-12
RU2020112502A3 (https=) 2021-10-08
EP3692048A4 (en) 2021-10-20

Similar Documents

Publication Publication Date Title
KR102782200B1 (ko) 인터페론 유전자 조절인자의 자극제로서의 환식 다이-뉴클레오타이드
KR102789862B1 (ko) Sting 활성과 연관된 상태 예컨대 암의 치료를 위한 시클릭 디뉴클레오티드
CN110382515B (zh) 经修饰的环状二核苷酸化合物
KR102849047B1 (ko) 피롤로피리미딘 itk 억제제
AU2019222026A1 (en) Pyrimidine-fused cyclic compound, preparation method therefor and application thereof
JP2022509149A (ja) ピリミジンと５員窒素ヘテロ環の誘導体、その製造方法、およびそれらの医学的使用
CN112888696B (zh) 外核苷酸酶抑制剂及其使用方法
CA3017524A1 (en) Cyclic di-nucleotide compounds and methods of use
EP3952870A1 (en) Phosphatidylinositol 3-kinase inhibitors
CA3225285A1 (en) Pi3k.alpha. inhibitors and methods of use thereof
JP7706795B2 (ja) Ｔｌｒ７アゴニスト
CN111989338A (zh) 修饰的环二核苷酸化合物
US20240066133A1 (en) Therapeutic agents and conjugates thereof
HK40022356A (en) Cyclic di-nucleotides as stimulator of interferon genes modulators
HK40022356B (en) Cyclic di-nucleotides as stimulator of interferon genes modulators
CN115427051B (zh) 治疗剂及其结合物
RU2817014C2 (ru) Агонисты tlr7
AU2010242394B2 (en) Purine derivative and antitumor agent using same

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200324

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210701

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231030

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240709

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250214

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250311

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250312

End annual number: 3

Start annual number: 1

PG1601 Publication of registration